Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is the leading global generic drug manufacturer with a strong presence in North America, Europe, Japan, and other key international markets. Their diversified portfolio of both generic and innovative medicines, along with their strong contract manufacturing and distribution services, positions them for continued growth and success. Teva's focus on expanding their biosimilars business through partnerships and their pipeline of promising treatments, such as their TL1A-targeting drug, Duvakitug, is expected to drive multiple expansion and long-term growth. Initiatives to improve their capital structure and mitigate loss of exclusivity risks further support a positive outlook for the company.

Bears say

Teva Pharmaceutical Indus is facing multiple legal and financial challenges, including potential loss of patent protection for its best-selling drug Copaxone, increasing competition in the generic drug market, and ongoing lawsuits and legal battles which may impact its revenue and profitability in the coming years. Additionally, Teva's acquisition of businesses has resulted in significant debt and negative cash flow, putting further strain on the company's financials. Overall, these factors contribute to our negative outlook on Teva's stock.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.